Home » NASTECH PHARMA ENTERS DEVELOPMENT DEAL WITH AMYLIN PHARMA

NASTECH PHARMA ENTERS DEVELOPMENT DEAL WITH AMYLIN PHARMA

June 26, 2006

Nastech Pharmaceutical Company Inc. entered a agreement with Amylin Pharmaceuticals, Inc. to develop a nasal spray formulation of exenatide. StreetInsider.com (http://www.streetinsider.com/news.php?id=988986&st=p)

KEYWORDS FDAnews Drug Daily Bulletin

07Dec
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
08Dec
Simplifying Oncology Trials: Make the Most of Remote Monitoring and Decentralization
08Dec
Extractables and Leachables: Taking a Deeper Dive
09Dec
Drug Safety Reporting Requirements: Best Practices for Monitoring, Reporting and Avoiding Regulatory Missteps
15Dec
Promoting & Marketing in the Digital and Virtual World: What Regulatory, Compliance & Marketing Professionals Need to Know

NASTECH PHARMA ENTERS DEVELOPMENT DEAL WITH AMYLIN PHARMA

Upcoming Events

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Simplifying Oncology Trials: Make the Most of Remote Monitoring and Decentralization

Extractables and Leachables: Taking a Deeper Dive

Drug Safety Reporting Requirements: Best Practices for Monitoring, Reporting and Avoiding Regulatory Missteps

Promoting & Marketing in the Digital and Virtual World: What Regulatory, Compliance & Marketing Professionals Need to Know

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Pfizer Sues Ex-Employee for Allegedly Stealing 12,000 Company Files

Cardiovascular Systems Recalls Wirion Embolic Protection System Due to Filter Breaks

Ocugen Faces Setback on Launching U.S. Trial of COVID-19 Shot

Hyperfine Gets FDA’s 510(k) Clearance for ‘Deep Learning’ Portable MRI

The Revised ICH E8: A Guide to New Clinical Trial Requirements